Phase II trials (DIRECT, BREAKFAST) showed improved outcomes in TNBC and HER2-negative BC patients undergoing NAC with FMD [203–205], and follow-up trials (BREAKFAST-2, DIRECT2) are underway. The gene discussed is ERBB2; the disease is breast cancer.